AlloVir is a late clinical-stage cell therapy company developing allogeneic T-cell therapies to treat and prevent viral diseases. Co.'s key product candidate, Viralym-M, is a multi-VST therapy targeting five viruses: BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. ALVR106 is Co.'s second multi-virus-targeted off-the-shelf VST product candidate that it developed to target respiratory diseases. ALVR109 is an allogeneic, off-the-shelf single virus-targeted cell therapy designed to target SARS-CoV-2. Co. is also developing ALVR107 designed to target hepatitis B, or HBV, infected cells and treat chronic HBV infections and ALVR108 to treat human herpesvirus-8. The ALVR stock yearly return is shown above.
The yearly return on the ALVR stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ALVR annual return calculation with any dividends reinvested as applicable (on ex-dates).
|